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The metabolically healthy obesity (MHO) phenotype is partly influenced by race/ethnicity and 
genetic factors being relatively more prevalent in some groups compared to others. This review 
examines current evidence on the prevalence of MHO amongst children, adolescents and adults 
of different racio-ethnic groups; and explores gene variants and single nucleotide 
polymorphisms (SNPs) that may confer cardioprotection in some racio-ethnic groups compared 
to others. Literature search of articles published in English was conducted using PubMed, 
Medline and Google scholar databases, with search terms related to the prevalence of 
metabolically healthy obesity as well as genetic variants that decrease or increase the risk of 
metabolic syndrome (MetS).  MHO prevalence differed across racio-ethnic groups and gene 
variants that confer cardioprotection were higher in some racio-ethnic groups compared to 
others. Lower prevalence of MHO across all ages was particularly reported in the Middle East, 
while high prevalence was reported in Africans, Americans and some Asian adult population. 
Excluding environmental and other risk factors, we observed that Caucasians were carriers of 
gene variants that confer protection against cardiometabolic diseases, whilst Asians showed high 
frequency of gene variants that increase susceptibility to MetS. A robust understanding of the 
role of these gene variants, their frequency distribution and racio-ethnic variations may facilitate 
conceptualisation of appropriate genome wide association studies (GWAS) to determine 
significant associations between various genetic factors and observed phenotype or disease. This 
will guide policy formulation and serve as a useful tool in pharmacogenomics and precision 
medicine. 
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INTRODUCTION   
Overweight and obesity are defined as unusual or excessive 
fat accumulation that may impair health (WHO, 2020). The 
body mass index (BMI) is commonly used to classify 
overweight and obesity in adults and it is defined as a person’s 
weight in kilograms divided by the square of their height in 
metres (kg/m2). World health organisation (WHO) defines 
overweight as a BMI ≥ 25 kg/m2 and obesity as BMI ≥ 30 
kg/m2, while obesity in adults is categorized into class 1 (30-
34.9 kg/m2); class 2 (35-39.9 kg/m2) and class 3 (≥ 40 kg/m2) 
(WHO, 2020). In children under five years of age overweight 





deviations (> +2SD) and obesity is weight-for-height 
greater than three standard deviations (> +3SD). For 
children aged between 5-19 years, overweight is BMI-
for-age greater than one standard deviation (> +1SD) 
above the WHO growth reference median, and obesity is 
greater than two standard deviation (> +2SD) above the 
WHO growth reference median (WHO, 2020). The BMI 
does not correspond to the same degree of fatness in 
different individuals. Other measures, such as waist 
circumference (WC) are better predictors of 
cardiovascular disease (CVD) risk than BMI. 
Abdominal overweight is given as (WC 95-102 cm in 
men; and 81-88 cm in women) and obesity (> 102 cm in 
men; and > 88 cm in women) (WHO, 2011). ]. For adults 
aged 70 and above, 106 cm in men; and 99 cm in women 
as cut-offs for abdominal obesity has been suggested by 
(Heim et al., 2011). 
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The global prevalence of obesity has grown to epidemic 
proportions as it affects about 775 million people 
worldwide including adults, adolescents and children 
(Kumar, 2019). Obesity is associated with metabolic 
diseases including insulin insensitivity, high blood 
glucose or diabetes, dyslipidaemia and non-metabolic 
diseases including some cancers (pancreatic, liver, 
colorectal, post-menopausal breast cancer, kidney and 
endometrial cancers), osteoarthritis, polycystic ovarian 
syndrome, non-alcoholic fatty liver disease and 
pulmonary disease (Dobbins, Decorby and Choi, 2013; 
Upadhyay et al., 2018). By far, perhaps the most 
important association of obesity is with CVD, though its 
contribution to overall mortality from CVD is still 
debated (Muñoz-Garach et al., 2016). The obese are a 
heterogenous group in relation to risk of metabolic 
syndrome (MetS). Risk of CVD is determined by MetS, 
which comprise a range of abnormalities including high 
blood pressure (HBP), dyslipidaemia, high fasting 
plasma glucose (FPG) concentration, inflammation and 
insulin resistance (IR) (Muñoz-Garach, Cornejo-Pareja 
and Tinahones, 2016). Interestingly, there is a subset of 
obese individuals characterised by an apparent 
decreased susceptibility to MetS. This category of 
individuals are referred to as the metabolically healthy 
obese (MHO), a term first described over fifteen years 
ago (Sims, 2001). Subsequently, a consensus MHO 
definition has been established in children and 
adolescents (Table 1) (Damanhoury et al., 2018), but not 
in adults. Several definitions have been proposed in 
adults (Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults, 2001; 
Karelis, Brochu and Rabasa-Lhoret, 2004; Meigs et al., 
2006; Aguilar-Salinas et al., 2008; Wildman et al., 2008) 
as shown in Table 2. Metabolic health is influenced by 
lifestyle, environment, physical fitness, ethnicity, gender 
and age but these factors are yet to be included in the 
definition of MHO (Blüher, 2014).  
 
Table 1. Consensus definition of metabolically healthy 
obesity in children and adolescents (ages 5-19 years). 
 
Cardiometabolic variables Values 
HDL-C, mg/dL  > 40  
TAG, mg/dL ≤150 
BP (SBP and DBP) ≤ 90th percentile 
FPG, mg/dL <100 
   Adapted from: Damanhoury et al., 2018. 
 
Table 2. Criteria for defining metabolic health status in obese adults  
Metabolic components  Aguilar-Salinas 
et al., (2008) 
Wildman et al., 
(2008) 





Meigs et al., (2006) 
BP, mmHg  < 140/90 and no 
treatment 
≥ 130/85 or 
treatment 
 130/85 or 
treatment 
≥ 130/85 or treatment 
WC, cm    ≥ 102 (M) 
≥ 88 (F) 
≥ 102 (M) 
≥ 88 (F) 
TAG, mg/dL  ≥ 150  ≤ 150 ≥ 150 ≥ 150 




≥0 < 40 (M) 
< 50 (F) 
<40 (M) 
<50  (F) 
FPG, mg/dL <126 and no 
treatment 
≥ 100 or 
treatment 
 ≥ 100 or 
treatment 
≥ 100 or treatment 
TC, mg/dL    ≤201    
LDL-C, mg/dL   ≤ 101   
HOMA-IR  >90th percentile <1.95   
HsCRP, mg/L  >90th percentile    
MH criteria All of the above <2 of the above ≥4 of the above ≤3 of the above <3 of the above 
 
BMI, body mass index; BP, blood pressure; F, female; FPG, fasting plasma glucose; HDL-C, high density lipoprotein-
cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-
C, low density lipoprotein-cholesterol; M, male; MH, metabolically healthy; NCEP: ATPIII, National Cholesterol Education 
Program-Third Adult Treatment Panel; TAG, triacylglycerol; TC, total cholesterol; WC, waist circumference. 
 
The exact mechanism(s) underlying this heterogeneity in 
the obese is still not clearly understood. However, 
studies have reported that both race/ethnicity and genetic 
predisposition in part, are capable of influencing the 
MHO phenotype (Forouhi and Sattar, 2006; Berezina et 
al., 2015). Racio-ethnic differences in the risk of MetS, 
atherosclerosis, CVD and lipid metabolism have been 
reported (Forouhi and Sattar, 2006). The observed 
differences in various racio-ethnic groups may result 
from differences in inflammatory markers, visceral  
adiposity, body fat distribution, IR, adiponectin and  
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plasma homocysteine concentration (Forouhi and Sattar, 
2006). 
The genetic predisposition of an individual could 
possibly provide clues and explain the marked 
differences in the risk of MetS across racio-ethnic 
groups. Numerous gene variants (mostly single 
nucleotide polymorphisms, SNPs) are associated with 
various components of MetS and eventually modify a 
population’s risk to MetS by affecting different critical 
metabolic pathways (Chang et al., 2018). Whilst the role 
of gene variants and SNPs associated with the risk of 
MetS in certain populations have been described (Zadjali 
et al., 2013; Zhou et al., 2016), data on the frequency 
distribution of these genetic factors in explaining the 
prevalence of MHO amongst different racio-ethnic 
groups are limited. Such data would contribute to our 
understanding of the biological variations caused by 
gene variants. This may explain the predisposition of 
some populations to decreased risk of MetS, which is 
required to formulate racio-ethnic specific guidelines on 
primary and secondary prevention of MetS. It could also 
identify more appropriate screening, diagnostic and 
treatment strategies in specific populations. Hitherto, 
whether MHO individuals have some specific gene 
variants or polymorphisms that confer cardioprotection 
in different racio-ethnic group is poorly investigated. 
Therefore, in this review, we examined the prevalence 
of MHO in different racio-ethnic groups amongst 
children, adolescents and adults. We also attempted to 
identify possible gene variants and SNPs that 
comparatively confer cardioprotection and increase the 
prevalence of MHO in certain racio-ethnic groups. 
 
Literature search 
A literature search was performed from April 2019 to 
March 2020 on PubMed, MEDLINE and Google 
Scholar databases, using multiple search terms including 
obesity; MHO; prevalence of MHO in children, 
adolescents and adults;  prevalence of the MHO 
phenotype in different ethnicities; racial and ethnic 
disparities in the prevalence of MetS; and genetic 
variants in MetS. A search was also conducted for 
ethnicity and pathogenesis of MHO among children, 
adolescents and adults; genetic variants that contribute 
to the risk of MetS in different racio-ethnic group as well 
as for global frequency distribution of identified genes 
and the association between SNPs, MetS and MHO. 
There was no restriction on date of publication and only 
articles written in English were included. 
 
MHO prevalence in children and adolescents of different 
racio-ethnic groups 
Until 2018, there was no standard MHO definition in 
children and adolescents (Damanhoury et al., 2018) and 
only those with obesity fulfilling all of the 
cardiometabolic criteria shown in table 1 were classified 
as having MHO (Sims, 2001). However, no agreement 
has been reached for FPG, even though an FPG of  ≤ 100 
mg/dL (≤5.6 mmol/L) was the most commonly used 
criteria in previous studies of MHO in children and 
adolescents (Damanhoury et al., 2018). Racio-ethnic 
specific differences have been reported in the prevalence 
of MHO in children and adolescents. An Italian study of 
1201 obese children and adolescents aged 4-18 years, 
which employed the proposed consensus definition of 
MHO reported a prevalence of 39% (Genovesi et al., 
2020). The estimated prevalence of MHO in children 
and adolescents differed significantly in previous 
studies, largely due to variations in definitions 
employed. Since we could not find a systematic review 
and meta-analysis on prevalence of MHO in children 
and adolescents of different racio-ethnic groups, 
findings of individual studies were reported instead 
(Table 3). 
 
A cross-sectional study of 340 overweight adolescents 
in Brazil and Colombia aged 10-18 years reported an 
MHO prevalence of 49.4% and 55.9% (Remor et al., 
2019). A study performed among 1047 obese children 
and adolescent below 19 years in the Eastern 
Mediterranean region of the Kingdom of Saudi Arabia 
found up to 23.8% and 20.9% to be metabolically 
healthy (Nasreddine et al., 2018). Similarly, another 
Middle Eastern study in 230 obese Israeli children and 
adolescent (median age 9.9 years) reported an MHO 
prevalence of 20.9% (Margolis-Gil et al., 2018). An 
MHO prevalence of 35.4% has been reported in 659 
overweight and obese European adolescents (González-
Gil et al., 2018). A retrospective study among 189 obese 
children and adolescents (ages 4-19 years) of African 
American/Caribbean descent in the USA reported an 
MHO prevalence of 38% (Khokhar et al., 2017). Data 
from the fourth Korea National Health and Nutrition 
Examination Survey of 530 obese children and 
adolescents (aged 10-19 years) found an MHO 
prevalence of 35.4% (Yoon et al., 2017). A large 
longitudinal study conducted in Germany of 2017 obese 
children (mean age: 11.6 ± 2.8 years) reported an MHO 
prevalence of 49.3% (Reinehr et al., 2015). 
Additionally, a cross-sectional study conducted in 
Canada reported an MHO prevalence of 21.5-31.5% in 
181 overweight obese children and adolescents aged 8-
17 years (Prince et al., 2014). Furthermore, an MHO 
prevalence of 68% was reported from data of 225 obese 
adolescents (aged 12-18 years) collected from the USA 
National Health Nutrition Examination Survey of 2003-
2004 and 2005-2006 (Camhi et al., 2013). 
 
Overall, the prevalence of MHO was lowest in the Saudi 
Arabian and Israeli studies, suggesting majority of the 
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child–adolescent obese population in this region would 
be metabolically unhealthy (Table 3). This finding is 
supported by that of (Friend, Craig and Turner, 2013) 
who reported a higher prevalence of MetS in the Middle 
East compared to Europe and the Far East. Similarly, a 
meta-analysis of 59 cross-sectional studies in Middle-
East countries reported high prevalence of MetS -  
Turkey (44%), Saudi-Arabia (16-41%), Qatar (26-33%), 
Kuwait (9-36%), Emirate (22-50%), Iran (6-42%), and 
Yemen (23%) (Ansarimoghaddam et al., 2018). 
 
 
Table 3. MHO prevalence in children and adolescents of different racio-ethnic groups. 
 BP, blood pressure; CMRF, cardiometabolic risk factor; FBG, fasting blood glucose; HDL-C, high density 
lipoprotein-cholesterol; IDF, international diabetes federation; IR, insulin resistance; MetS, metabolic syndrome; 









MHO definition used MHO prevalence 
Genovesi et al., 
2020, Italy 
Caucasians 1201 obese 
children and 
adolescents 
Based on definition proposed 
by Damanhoury et al. 2018 
 
39% 
Remor et al., 
2019, Brazil and 
Columbia.   




Absence of both MetS 




al., 2018, Spain 
Caucasians 659 overweight 
and obese 
adolescents 
Based on age and sex cut off 
for FBG, BP, TAG and HDL-
C 
35.4% 
Margolis et al., 
2018. 
Israel 
Jews 230 obese children 
and adolescents 
Based on CMRF clustering: 
BP, serum lipids and glucose 
20.9% 
Nasreddine et al., 
2018, Saudi 
Arabia. 
Arabians 1047 obese 
children and 
adolescents 
Based on absence of both 
CMRF and IR according to 
IDF criteria (Zimmet et al., 
2007). 
 
23.8% & 20.9% 
respectively 








Yoon et al., 
2017, Korea. 
Asians 530 obese children 
and adolescents 
Absence of IR and CMRF 
using IDF criteria (Zimmet et 
al., 2007)  
68.8% and 36.8% 
respectively. 
Reinehr et al., 
2015, Germany 
Caucasians 2017 obese 
children 
Absence of hypertension, 
dyslipidaemia and impaired 
fasting glucose 
49.3% 
Prince et al., 
2014, Canada 
Caucasians 181 obese children 
and adolescents 
Obesity with no CMRF and 
obesity with HOMA-IR of ≥ 
3.16 
31.5% & 21.5% 
respectively 
Camhi et al., 
2013, USA.  
Non–Hispanic white and 




Absence or one CMRF: 




MHO prevalence in adults of different racio-ethnic 
groups 
Due to lack of a standard MHO definition and disparity 
of employed criteria, establishing an accurate or 
standard prevalence of MHO in adults in different 
studies and racio-ethnic groups has been challenging 
(Liu et al., 2019). A meta-analysis of 40 population-
based investigations and intervention studies performed 
in Europe, Southeast Asia, Middle East, Africa, North 
and South America and Australia, observed an overall 
MHO prevalence of 35% in obese adults (Lin et al., 
2017). Some regions were reported to have a higher 
prevalence as observed in Africans followed by South 
Americans (Table 4). However, in this meta-analysis, 
only one study each was conducted in both Africans and 
South Americans. There was a similarity between MHO 
prevalence in Southeast Asia, North America and 
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 Australia, and the lowest MHO prevalence was 
recorded in Europe and the Middle East (Lin et al., 
2017). Included studies defined metabolic health based 
on age and gender-specific cut-offs of metabolic 
components defined by the Third Report of National 
Cholesterol Education Program’s Adult Treatment Panel 
(NCEP ATP III) or International Diabetes Federation 
(IDF) i.e. systolic blood pressure (SBP), diastolic blood 
pressure (DBP), high-density lipoprotein -cholesterol 
(HDL-C), triacylglycerol (TAG), and FPG (NCEP-ATP 
III 2001).  
As reported in children and adolescents, a lower MHO 
prevalence has also been found in adults from the Middle 
East. The distinct patterns of fat distribution by ethnicity 
may influence the variation observed amongst different 
ethnic groups as Blacks are shown to have less visceral 
abdominal fat accumulation compared to their White 
counterparts (Rahman et al., 2009; Heymsfield et al., 
2016). The higher MHO prevalence in Africans is also 
supported by lower prevalence of MetS in Blacks 
(Krishnadath et al., 2016). Low prevalence of MetS in 
Blacks occurs despite higher rates of IR, inflammation,  
and HBP (Deboer, 2011), but lower tendency for 
dyslipidaemia, central obesity and increased FPG 
concentration (Walker et al., 2012).  
 
Additionally, a worldwide meta-analysis of 32 
population based cross-sectional and longitudinal 
studies consisting of obese Europeans, Asians and 
Americans reported an MHO prevalence of 28.5% 
(Wang et al., 2015). The American population had the 
highest MHO prevalence and included studies employed 
seven definitions of metabolic health including 
definitions by Meigs (Meigs et al., 2006), Wildman 
(Wildman et al., 2008), Aguilar-Salinas (Aguilar-
Salinas et al., 2008), Guerrero (Guerrero-Romero and 
Rodriguez-Moran, 2013), Calori (Calori et al., 2011), 
Soriguer (Soriguer et al., 2013) and Hamer (Hamer, 
Batty and Kivimaki, 2012). Furthermore, a systematic 
review of 27 population-based studies conducted in 
Asia, Europe, North America and Oceania reported a 
MHO prevalence of 6-75% (Rey-López et al., 2014). 
The included studies employed 30 different definitions 
of metabolic health, with the definition by Karelis et al. 
2004 that included five cardiometabolic factors i.e. 
triglycerides, HDL-C, LDL-C, total cholesterol and 
HOMA-IR with stricter diagnostic criteria  (4 out of 5) 
(Karelis et al., 2004) being the most commonly used. 
However, majority (96%) of included studies did not 
report the 95% confidence interval for MHO prevalence. 
Some ethnic groups had healthier metabolic profile 
compared to others and MHO prevalence was higher in 
Asians compared to Caucasians or people of multi-
ethnic origin (Rey-López et al., 2014). This observation 
is contradictory, since Asians are particularly more 
prone to abdominal obesity and visceral fat 
accumulation and are at a higher risk of type 2 diabetes 
mellitus (T2DM) and CVD compared to Europeans 
(Misra and Vikram, 2004; Misra and Khurana, 2009). 
Amongst the prevalence rates stated for the 
aforementioned meta-analysis, only (Lin et al., 2017) 
included a study in Africans. Thus, there is limited data 
on the prevalence of MHO in Africans, as they have 
seldom been included in existing studies. 
 
Possible genetic basis for the racio-ethnic disparities in 
MHO. 
As earlier stated, MHO prevalence show racio-ethnic 
disparities. It was observed to be particularly low in 
children and adolescents from Middle East. Adult rates 
are higher in Africans and South Americans, but lower 
in Europeans and Middle easterners (Table 4). It is 
important to note that the possible genetic mechanisms 
that could contribute to a high prevalence of MHO could 
be inherited at birth and persist through adulthood.    
 
Table 4.    Prevalence of metabolically healthy obesity 




Adapted from (Lin et al., 2017). 
 
It is believed that certain gene variants and SNPs exist 
that confer protection against cardiometabolic diseases 
or decrease the risk of MetS (Schlauch et al., 2019). 
Some racio-ethnic groups may have a higher frequency 
of these cardioprotective gene variants. The study by 
(Schlauch et al., 2019) appears to be the first and perhaps 
the only study to genetically screen 38 metabolically 
healthy American class 2 and 3 obese women of 
European descent for SNPs that confer protection to the 
development of cardiometabolic disease. This study 
found SNPs in KCNQ1 and TOX2 to likely confer this 
protection. Thus, there is need to identify candidate gene 
variants and SNPs that may confer protection to the 
development of MetS or specifically related to MHO. In 
this review, we identified and discussed nine genes and 
their gene variants or SNPs that may possibly affect 
MetS risk and are associated with the MHO phenotype. 
These include: TOX high mobility group box family 
member 2 (TOX2), Potassium voltage-gated channel 
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subfamily Q member 1 (KCNQ1), 
methylenetetrahydrofolate reductase (MTHFR), 
adiponectin (ADIPOQ), dual specificity protein 
phosphatase 10 (DUSP10), leptin (LEP) and leptin 
receptor (LEPR), bromodomain containing protein 2 
(BRD2), cholesteryl esteryl ester-transfer protein 
(CETP) and Apolipoprotein A5 (APOA5) genes (Fig. 1).  
 
 TOX high mobility group box family member 2 (TOX2) 
gene 
Decreased expression of TOX2 gene may decrease MetS 
risk, as three SNPs (rs766622, rs6065690 and 
rs6093921) in an intronic region of TOX2 gene have 
been reported to be associated with the MHO phenotype 
in 38 metabolically healthy class 2 and 3 obese 
American women of European descent (Schlauch et al., 
2019). TOX2 is located on chromosome 20q13 and 
indirectly regulates TBX21 (T-bet, a T-box transcription 
factor family member that regulates immune cell 
differentiation and function) by decreasing its 
expression (Stolarczyk, Lord and Howard, 2014; Vong 
et al., 2014). TBX21 is the primary transcription factor 
for T-helper 1 (Th1) cell development and plays a 
critical role in activation of innate immune cells such as 
dendritic, lymphoid, natural killer (NK) and T-cells 
(Garrett et al., 2007). TBX21 regulates the balance 
between Th1 and Th2 responses in inflammatory 
diseases (Buono et al., 2005), and transactivates the 
interferon-γ (IFN-γ) gene (Szabo et al., 2002). An 
imbalance of Th1/Th2 cells has been observed with 
increasing adiposity as adipose tissue contain immune 
cells in the stromalvascular fraction (Ferrante, 2013; 
Stolarczyk, Lord and Howard, 2014).  
Decreased TBX21 gene expression may be associated 
with MHO, as T- bet deficient (T-bet−/−) mice with 
increased visceral fat display altered adipose tissue 
immune cell infiltration, reduced proinflammatory 
cytokines, lower fasting insulin concentration, and better 
glucose tolerance, hence were more insulin sensitive 
compared to wild type (WT) mice (Stolarczyk et al., 
2013). This suggest that polymorphisms that lead to 
decreased TOX2 expression may indirectly affect 
obesity through a TBX21-dependent mechanism. 
Potential mechanisms through which TBX21 (T-bet) 
may improve insulin sensitivity are as follows: First, 
through reduced secretion of IFN-γ, which has been 
reported to improve glucose homeostasis and cytokine 
expression in diet-induced obesity (O’Rourke et al., 
2012), suggesting a role for IFN-γ in regulating 
inflammation and glucose homeostasis in obesity. 
Second, through its interaction with forkhead box P3 
(Foxp3+) T cells (Tregs), as the anti-inflammatory 
action of Tregs alters insulin sensitivity (Feuerer et al., 
2009). Due to limited data on the association between 
TOX2 gene and metabolic health in humans, we could 
not assess the prevalence of MHO in different racial or 
ethnic groups in relation to TBX21. Hence, there is need 
for more genetic studies to evaluate the role of TOX2 
gene in MHO. 
 
Potassium voltage–gated channel subfamily q member 1 
(KCNQ1) gene 
A SNP in KCNQ1 has been reported to be associated 
with MHO phenotype (Schlauch et al., 2019). KCNQ1 is 
located on chromosome 11q15 and encodes a protein 
that is essential for the repolarization phase of cardiac 
action potential (Al-Shammari et al., 2017; Liu et al., 
2018). Hence, polymorphisms in KCNQ1 may impair 
heart function, resulting in increased risk of CVD 
(Fosmo and Skraastad, 2017). It has been implicated in 
various cardiac dysfunctions caused by abnormal lipid 
metabolism (Chen et al., 2010), familial atrial 
fibrillation (Bartos et al., 2013) and long QT syndrome 
(Hajjar and Hulot, 2014). Gene variants in KCNQ1 may 
also be involved in the metabolism and balance of blood 
glucose, following its significant association with 
impaired FBG or haemoglobin A1c (HbA1c) (Qi et al., 
2009). Polymorphisms in KCNQ1 may also be 
responsible for impaired pancreatic β-cell function 
(Rosengren et al., 2012) and reduced insulin secretion 
following an oral glucose load overtime (Holmkvist et 
al., 2009), and thus predispose to T2DM (Yasuda et al., 
2008; Scott et al., 2017).  
Several variants of KCNQ1 (>600 disease associated 
variants) have been found but variants rs2237892, 
rs227897 and rs2237897 have the strongest association 
with MHO. Of these, KCNQ1 rs2237892 is the most 
widely studied and is significantly associated with 
increased T2DM risk in Europeans, Americans and 
Asian population (W. Zhang et al., 2015). Of the various 
KCNQ1 rs2237892 alleles (CC, CT and TT), the CC 
allele has been reported to increase the susceptibility to 
T2DM by influencing β cell function and insulin 
secretion (Li, Wang and Lu, 2014), as well as increased 
hypertension and macrovascular complications in 
Chinese Han patients with T2DM compared to alleles 
TT and CT (W. Zhang et al., 2015). This may suggest 
that increased MetS risk is found in individuals or racio-
ethnic groups with a high frequency distribution of the C 
allele of rs2237892 variant, while reduced risk of MetS 
would be associated with T allele of rs2237892. A lack 
of association of KCNQ1 rs2237892 with T2DM has 
also been reported in Saudi population and North 
African Arabs (Turki et al., 2012; Al-Shammari et al., 
2017). However, studies of KCNQ1 rs2237892 C-T 
polymorphism among people of African descent and the 
Middle East is currently limited. Other studies have 
shown people of Asian descent to have a higher 
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frequency of KCNQ1 rs2237892 CC allele (Li, Wang 
and Lu, 2014). 
Methylenetetrahydrofolate reductase (MTHFR) gene  
Polymorphisms in MTHFR have been reported to 
increase risk of MetS, thereby worsening metabolic 
health (LI et al., 2011). A meta-analysis of 30 case-
control studies found MTHFR C677T (rs1801133) 
polymorphism to be associated with risk of myocardial 
infarction (MI) in young and middle-aged Caucasians 
(Xuan et al., 2011). MTHFR gene located on 
chromosome 1p36.3 (Wan et al., 2018) modulates 
homocysteine (Hcy) metabolism, due to its ability to 
maintain normal serum/plasma Hcy concentration 
(Trimmer, 2013). Increased circulating Hcy 
concentration may increase the risk of MetS by 
producing oxygen-free radicals which stimulates the 
proliferation of vascular smooth muscle cells, inducing 
IR and damaging vascular endothelial cell function. This 
results in increased plasma C-reactive protein levels, 
promotion of lipid peroxidation, and a decrease in APO-
A1 expression, thereby affecting other 
pathophysiological processes (Hajer et al., 2007). Hcy 
may induce apoptosis of endothelial progenitor cells via 
enhancement of endoplasmic reticulum stress-mediated 
activation of caspase-3. Hcy exposure can weaken the 
viability of insulin-secreting cells, reduce glucokinase 
phosphorylating ability, and decrease insulin secretory 
responsiveness leading to cell death (Huang et al., 
2013).  
 
Several SNPs in MTHFR have been described but 
C677T (rs1801133) is the most studied and clinically 
relevant (El Shafie et al., 2017). This SNP is the most 
common genetic cause of Hyper-homocysteinemia 
(HHcy), which has been implicated in the pathogenesis 
of atherosclerosis (LI et al., 2011) . This polymorphism 
causes the enzyme to become thermolabile with 50-
70% reduced MTHFR enzyme activity and HHcy 
particularly in the presence of low dietary folate 
(Munisamy et al., 2015). Among the various allele types 
of MTHFR C677T (CC, CT and TT), individuals who 
are homozygous for TT allele have an increased risk of 
HHcy (Wang et al., 2018), hypertension (Ward et al., 
2011), T2DM (B. Zhu et al., 2014) and dyslipidaemia 
(Real et al., 2009). This has been confirmed in a Chinese 
population where the TT allele carriers had 1.6 times 
higher risk of developing MetS than did CC allele 
carriers (Wang et al., 2018). This finding may suggest 
that MHO individuals would have less occurrence of the 
TT allele and a higher incidence of the CC indicating 
that the CC and CT allele may confer protection against 
MetS. However, this hypothesis has not been 
investigated in MHO individuals. 
 
The frequency of MTHFR C677T particularly the 
homozygous T allele varies in different geographical 
regions and ethnic groups (Botto and Yang, 2000). A 
north-to-south increase in allele frequency was observed 
in Europe (Botto and Yang, 2000) with the allele 
frequency reported to be 0.07 in sub-Saharan Africans 
and 0.06 in Canadian Inuit, whilst in whites, Japanese, 
and Chinese, the allele frequencies ranged from 0.24–
0.54 (Hegele et al., 1997; Pepe et al., 1998). More 
recently, a meta-analysis of 62 studies reported the 
lowest frequency of MTHFR C677 TT allele in Africans 
(10.3 %), and highest in Europeans (34.1 %) (Yadav et 
al., 2017). This could possibly contribute to the higher 
prevalence of MHO in Africans. Although these studies 
have not included frequencies in Arabians, evidence 
from global maps revealed that the highest 
polymorphism on MTHFR C677 TT allele were found in 
the Middle East (Iran and Saudi Arabia), Europe 
(Cyprus, Spain, Germany, Slovenia, and United 
Kingdom), Asia (Japan and China), and North America 
(Canada and United States) for the general healthy 
population (Gonzales, Yu and Shiao, 2017). This finding 
could also support the increase in MetS and decrease in 
MHO reported in children, adolescents and adults in 
Middle East. 
 
Adiponectin (ADIPOQ) gene 
Increased adiponectin concentrations have been 
observed in MHO women compared to their 
metabolically unhealthy counterparts, suggesting that 
high adiponectin concentrations may determine the 
favourable metabolic profile of the MHO (Tailor et al., 
2010). This indicates that gene variants and 
polymorphism in ADIPOQ that increase adiponectin 
concentration are crucial to improving metabolic health.  
Adiponectin gene, also known as ACRP30, ADIPOQ 
and GBP28 (Pajvani and Scherer, 2003), is located on 
chromosome 3q27 and regulates glucose concentration, 
fatty acid oxidation, cardiovascular function and 
improves IR, since it has anti-diabetic, anti-
inflammatory and anti-atherogenic properties (Ruan and 
Dong, 2016).  
Potential mechanisms by which adiponectin exerts its 
anti-atherogenic properties include: inhibition of the 
expression of adhesion molecules in endothelial cells, 
smooth muscle cell proliferation, differentiation of 
monocytes into macrophages, formation of foam cells 
and secretion of TNF-α by macrophages (Arita et al., 
2002; Lenz and Diamond, 2008). Adiponectin increases 
endothelial nitric oxide secretion (Chandran et al., 
2003), and exerts an anti-inflammatory effect through 
the activation of its three receptors - AdipoR1, AdipoR2, 
and T-cadherin (Robinson, Prins and Venkatesh, 2011). 
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The activation of AdipoR1 and R2 results in increased 
hepatic and skeletal muscle fatty acid oxidation, 
increased skeletal muscle lactate production, reduced 
hepatic gluconeogenesis, increased cellular glucose 
uptake, and inhibition of inflammation and oxidative 
stress (Robinson, Prins and Venkatesh, 2011). 
 
Several SNPs in ADIPOQ gene influence adiponectin 
concentration and are associated with risk of MetS (Jang 
et al., 2008). The most widely studied of these SNPs are 
ADIPOQ rs2241766 (+45 T > G in exon2) and 
rs1501299 (+276 G > T in intron2) (Melistas et al., 
2009). ADIPOQ rs1501299 SNP may decrease CVD 
risk (Yuan et al., 2016; Kanu et al., 2018; Song, Yoon 
and Kim, 2018), as homozygote TT for SNP rs1501299 
had a lower CVD risk than carriers of other genotypes 
(Menzaghi, Trischitta and Doria, 2007), and are 
protected from MI (Chiodini et al., 2010). Their 
protective role may be due to their ability to increase 
serum adiponectin concentration (Song, Yoon and Kim, 
2018; Christodoulou et al., 2020), suggesting that 
populations with this SNP would have a higher 
prevalence of MHO compared to those with a lower 
frequency. Unfortunately, there is limited data on the 
frequency distribution of SNP ADIPOQ rs1501299 T 
allele in different racio-ethnic groups, hence, conclusion 
on whether Africans or Asians are carriers of this 
protective gene variant could not be made. This may be 
attributed to lack genome wide association studies 
(GWAS) of the gene variant in different racio-ethnic 
groups.  
Given the reported high prevalence of MHO in Africans, 
Americans and some Asians, it would be expected that 
these ethnic groups would have higher adiponectin 
concentration. However, lower concentration of 
adiponectin have been reported in Blacks (10.4µg/mL) 
compared to Whites (14.9µg/mL) (Cohen et al., 2011). 
Additionally, adiponectin concentration are significantly 
higher in Canadians of European descent (12.96 ± 0.73 
µg/mL) and Aboriginal people (11.87 ± 0.41 µg/mL) 
than in South Asians (9.35 ± 0.43 µg/mL) and Chinese 
(8.52  ± 0.57 µg/mL) (overall P < 0.001) (Mente et al., 
2010). 
 
Dual specificity protein phosphatase 10 (DUSP10) gene 
Increased DUSP10 expression decreases the risk of 
MetS and may be associated with the MHO phenotype 
due to its potent anti-inflammatory properties (Arkan et 
al., 2005). DUSP10 also known as MAP kinase 
phosphatase 5 (MKP5) gene is located on chromosome 
1q41 and negatively regulates p38 MAPK and c-Jun N-
terminal kinase (JNK) through their dephosphorylation 
(Caunt and Keyse, 2013). DUSP10 is highly expressed 
in insulin responsive tissues including skeletal muscle, 
adipose tissue and liver of humans and mice, thus, it 
regulates obesity, inflammation, IR, insulin sensitivity 
suggesting a potential role in metabolic regulation (Y. 
Zhang et al., 2015). Increased DUSP10 promotes the 
dephosphorylation of JNK1 pathway resulting in 
improved metabolic health. Although this hypothesis 
has not been investigated in MHO individuals, 
overexpression of DUSP10 inhibits the development of 
inflammation in the liver preventing the onset of age‐
associated and diet‐induced non-alcoholic fatty liver 
disease (NAFLD) by inhibiting p38 activation. This 
results in decreased peroxisome proliferator-activated 
receptors (PPARγ) expression which in turn decreases 
hepatic lipid accumulation, inflammation, and fibrosis 
(Tang et al., 2019). Similarly, overexpression of 
DUSP10 in prostatic epithelial cells acts as an anti-
inflammatory protein, decreasing pro-inflammatory 
responses mediated by cytokine-dependent NF-kB 
activation, COX-2 expression, and cytokine (IL-6 and 
IL-8) (Nonn, Duong and Peehl, 2007). 
 
However, decreased DUSP10 expression promotes a 
phosphorylated JNK activation which has been reported 
to increase risk of MetS (Hirosumi et al., 2002). 
DUSP10 deficient mice have shown increased adiposity, 
developed glucose intolerance, impaired insulin 
sensitivity and increased expression of proinflammatory 
cytokines, including IL-1β, IL-6, TNF-α, and monocyte 
chemoattractant protein-1 (MCP-1) compared to age-
matched WT mice (Zhang et al., 2015). 
Although the role of DUSP10 gene in MHO humans has 
not been fully established, it is possible that enhanced 
expression of DUSP10 may exert some protection 
against MetS. However, it is not known if there is a 
differential expression of DUSP10 in people of Asian, 
African, Arabian and Caucasian descent. Although 
several DUSP10 SNPs including rs1118838, 
rs12724393, rs908858 and rs6687758 have been 
implicated in the risk of colorectal cancer (Zhang et al., 
2014), association with metabolic disease is yet to be 
determined. 
 
Leptin (LEP) & leptin receptor (LEPR) gene   
Though plasma leptin levels are higher in obesity, 
lower leptin concentration has been associated with 
MHO compared to their metabolically unhealthy 
counterparts (Tailor et al., 2010). Leptin and its receptor 
located on chromosome 1p31 function in regulating 
energy homeostasis (Schwartz et al., 2000). The 
physiological function of leptin is mediated by its 
receptor, which is a cytokine receptor that promotes gene 
transcription by activating signal transduction (Banks et 
al., 2000). They have been implicated in the 
pathophysiology of obesity, T2DM and cardiovascular 
homeostasis (Brennan and Mantzoros, 2006). LEP and 
LEPR variants may affect vascular tone in heart 
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or peripheral circulation, predisposing patients to 
hypertension and coronary artery disease (CAD) 
(Nowzari et al., 2018) due to their role in regulating lipid 
metabolism, blood pressure and angiogenesis 
(Boumaiza et al., 2012). 
Several SNPs have been identified in the coding and 
non-coding regions of the LEPR gene (Daghestani et al., 
2019). Of these SNPs, LEPR polymorphism Q223R 
(rs1137101) also known as Gln233Arg is the most 
frequently studied and is associated with impaired LEPR 
signalling capacity, with higher mean circulating 
concentrations of leptin (Ragin et al., 2009) and 
increased risk of MetS as it has been linked to 
dyslipidaemia (Okada et al., 2010), T2DM (Yang et al., 
2016) and atherosclerosis (Saukko, Kesäniemi and 
Ukkola, 2010). Populations exhibiting this 
polymorphism would less likely be metabolically 
healthy and may have higher leptin concentration. 
LEPR Q223R has three genotypes, AA, AG and GG with 
the GG allele increasing risk of lipid abnormalities and 
IR particularly in the obese. AA and AG genotypes 
modify the risk of hyperlipidaemia in obese Saudi 
women (Daghestani et al., 2019). Obese females with 
the AA genotype had the lowest leptin and insulin 
concentration compared to those with the GG genotype 
who also had higher homeostatic model assessment of 
insulin resistance (HOMA-IR) (Daghestani et al., 2019). 
The wild type A allele is highest in Saudis (0.798), 
British (0.610), Puerto Ricans (0.610), Colombians 
(0.520), Punjabi Pakistan (0.573), Lubya in Kenya 
(0.596), Tuscani in Italy (0.561), Europeans (0.531), 
Americans (0.563), East Asians including Chinese 
(0.131) and Japanese (0.154) (Daghestani et al., 2019).  
It is unexpected for Saudis to have a high frequency of 
the A` allele since Middle Eastern people were reported 
to have a low MHO prevalence across all age groups. 
However, the higher frequency of A `allele reported in 
this study was not associated with higher glucose 
concentration or IR (Daghestani et al., 2019). In 
addition, among the various ethnic groups represented, 
Asians have the lowest frequency of the A` allele 
suggesting increased MetS risk. According to (Bender et 
al., 2011) Q223R allele frequency is higher in Asians 
(80.6-95.0%) compared to 30.2-56.7% in Caucasians. 
Serum leptin concentration show ethnic variation, as 
they are significantly higher in South Asians (11.82  ±  
0.94 ng/mL) and Aboriginal people (11.13 ± 1.21 
ng/mL) than in Europeans (9.12 ± 0.85 ng/mL) and 
Chinese (8.25 ± 0.77 ng/mL) (overall P < 0.001) (Mente 
et al., 2010).  
 
Bromodomain containing protein 2 (BRD2) gene 
Animal models have shown decreased cardiometabolic 
risk following reduced expression of BRD2 gene (Wang, 
Deeney and Denis, 2013), suggesting that reduced 
expression of this gene could be associated with the 
MHO phenotype. The BRD2 is located on chromosome 
6p21 and is highly expressed in pancreatic β-cells, where 
it inhibits β-cell mitosis and insulin transcription 
(WANG et al., 2009). The BRD2 gene belongs to the 
bromodomains and extra terminal domain (BET) family 
of transcriptional co-regulators that modulates body 
energy balance and immune function (Taniguchi, 2016). 
There is evidence that genetically engineered mice 
deficient in Brd2 gene did not show inflammation and 
obesity-induced IR but exhibited improved glucose 
tolerance, increased adiponectin concentration, reduced 
macrophage infiltration in white adipose tissue and 
decreased blood glucose, resulting in improved 
metabolic profile devoid of T2DM gene (Wang, Deeney 
and Denis, 2013). MHO individuals show reduced levels 
of inflammation compared to other obese individuals, 
protecting them against IR and metabolic dysfunction 
(Belkina and Denis, 2010). Therefore, it is plausible that 
the MHO would have reduced expression of BRD2 gene. 
Whether the MHO have diminished expression of BRD2 
gene is yet to be established in humans. However, 
several SNPs have been observed in BRD2 gene 
including rs9276935, rs55912052 and rs516535 (Yavuz 
et al., 2012), but hitherto, none of these have been linked 
with metabolic health. 
 
Cholesteryl ester transfer protein (CETP) gene 
Polymorphisms in the CETP gene which results in 
decreased CETP expression are associated with 
improved CVD risk profile (Mabuchi, Nohara and Inazu, 
2014), indicating an association with MHO phenotype. 
Decreased plasma CETP activity has been reported to be 
anti-atherogenic as it increases plasma high density 
lipoprotein –cholesterol (HDL-C) concentration 
(Mabuchi, Nohara and Inazu, 2014). The human CETP 
gene is located on chromosome 16q21 and modulates 
lipid metabolism, particularly HDL-C (Wang et al., 
2013). Evidence in CAD patients show that CETP 
inhibitors increase HDL-C concentration (Lüscher, von 
Eckardstein and Simic, 2012).  
 
The CETP gene is highly polymorphic (Ridker et al., 
2009), with over 180 SNPs, but CETP Taq1B site 
rs708272 is the most widely studied (Thompson et al., 
2008). Of the various CETP Taq1B alleles (B1B1, B1B2 
and B2B2), carriers of Taq1B B2B2 genotypes had 
significant higher HDL-C concentration and lower mean 
CETP activity compared to carriers of Taq1B B1B1 
allele (Thompson et al., 2008). The Taq1B B2B2 tends 
to decreases the risk of MetS, hence, individuals with 
this variant may be metabolically healthier. A case 
control study found the absence of B2 allele to be 
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associated with a two-fold increased risk of CAD 
(Tayebi et al., 2013). This study discovered that Taq1B 
B2B2 genotypes conferred a significant reduced risk of 
coronary atherosclerosis due to its ability to raise plasma 
HDL-C concentration (Kashani Farid et al., 2010). 
Though the exact mechanism of the link between CETP 
SNPs to metabolic health is not clear, it could be via its 
association with plasma HDL-C concentration. HDL-C 
is protective of CAD and an inverse association has been 
recorded (Hausenloy and Yellon, 2008). HDL-C 
prevents the oxidation of LDL-C on endothelial cell and 
also induces endothelial cell to produce nitric oxide 
(Yuhanna et al., 2001).  
 
CETP Taq1B polymorphism varies in different ethnic 
group, the B2B2 allele frequency - Tunisians (0.29) 
(Rejeb et al., 2008), African Americans (0.26) (Cuchel 
et al., 2002), Europeans (0.43) (Gudnason et al., 1999), 
Americans (0.44) (Ordovas et al., 2000), Israelis (0.43) 
(Kark et al., 2000) and Taiwanese (0.42) (Hsu et al., 
2002). Interestingly, people of African descent had the 
lowest frequency of this cardioprotective gene variant, 
despite having a lower tendency of dyslipidaemia. 
Similarly, a study which compared the frequency of 
CETP Taq1 B2 allele between African Americans and 
Caucasians  found  lower frequencies in healthy African 
Americans (0.26 ) than in Caucasians (0.44); and 
patients undergoing cardiac catherization - African 
Americans (0.28) and Caucasians (0.38) (Cuchel et al., 
2002). It is important to note that Africans are under-
represented in most genetic studies and instead African 
Americans who are African with an admixture of 
Europeans have been used as the sole representative of 
African population. Much of what is currently reported 
about genetic diversity comes from Caucasian and Asian 
population. 
 
Apolipoprotein A5 (APOA5) gene 
In human and animal models, APOA5 gene expression is 
inversely associated with circulating plasma 
Triacylglycerol (TAG) concentration. Mice deficient in 
Apoa5 gene showed four times greater plasma TAG 
concentration, whereas the overexpression of APOA5 
gene led to 66% decrease in plasma TAG concentration 
(Merkel et al., 2005). Obese individuals exhibit lower 
APOA5 concentration suggesting an increased risk of 
CVD (Su, Kong and Peng, 2018). Apolipoprotein A5 
gene is located on chromosome 11q23 and regulates 
lipid metabolism, particularly plasma TAGs and HDL-C 
concentration (Li and Guo, 2014). Potential mechanisms 
through which APOA5 may contribute to increased risk 
of MetS include: decreasing HDL-C concentration (Cha 
et al., 2014) and modulating hepatic TAG metabolism 
and its secretion within hepatocytes (Olofsson, 2005). 
APOA5 attenuates the second step of very low-density 
lipoprotein (VLDL) particle maturation, vital for the 
formation of TAG rich VLDL, thereby impairing liver 
VLDL assemblage and secretion in hepatocytes 
(Walther and Farese, 2012). APOA5 was found to cause 
an increase in lipolysis by increasing lipoprotein lipase 
(LPL) activity and increased removal of TAG rich 
lipoproteins (Grosskopf et al., 2005).  
Of all the variants of APOA5 gene, rs662799 (-
1131T>C) is the most widely studied (W. Zhu et al., 
2014). APOA5 rs662799 contributes to a pro-
atherogenic lipoprotein profile, since it is associated 
with high TAG and reduced HDL-C concentration 
(Jiang et al., 2010). In 201 MetS patients, the -1131T 
allele gene variant of APOA5 significantly increased 
MetS risk compared to 210 healthy controls indicating 
this variant is a risk factor for increased TAG and 
development of MetS (Maász et al., 2007). This suggests 
that MHO individuals may have decreased prevalence of 
this variant but this hypothesis has not been investigated.  
 
The allele frequency of APOA5 rs662799 show inter-
ethnic variations. The minor allele of APOA5 rs662799 
has a greater frequency in Japanese and Chinese 
population compared to Caucasians (Aouizerat et al., 
2003). The CC and GG allele in APOA5 rs662799 show 
36.1% higher plasma TAG concentration and increases 
risk of MetS compared to the TT genotype  (Jiang et al., 
2010). According to the HapMap database, there are 
ethnic differences in APOA5 rs662799 G allele (A>G). 
The minor allele frequency in European populations 
(HapMap-CEU) is 1.7%, much lower than the 13.3% 
observed in individuals of African descent (HapMap-
YRI), 26.7% in Chinese (HapMap-CHB) and 28.9% in 
Japanese (HapMap-JPT) (Ye et al., 2015). A cross 
sectional study in North Iranian population reported a 
frequency of 5% close to that of Europeans (Halalkhor 
et al., 2014). The C allele frequency of APOA5 rs662799 
varies - Hungarian (8.5%)  (Maász et al., 2007), 
Japanese (35.3%) (Yamada et al., 2007), Hong Kong 
(28.6%) (Ong et al., 2011), Chinese (21.6%) (Xu et al., 
2013), Germany (7%) (Grallert et al., 2007), and 
Taiwanese (27.2%) (Lin et al., 2016). The frequency 
distribution of both G and C allele have shown higher 
and lower frequencies in Asians and Europeans 
respectively. This supports the high visceral fat 
accumulation and higher risk of T2DM and CVD 
observed in Asians compared to Europeans. 
We are aware that a vast majority of present-day humans 
across all continents, and in different racial/ethnic 
groups have notable mixed ancestry or ancestral 
heterogeneity, which supports admixture. For example, 
uniformly categorizing admixed African Americans 
(with ancestries from both Africa and Europe) with the 
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Figure 1. Genes possibly associated with metabolically 
healthy obesity phenotype.       ADIPOQ, Adiponectin; 
APOA5, Apolipoprotein A5; BRD2, Bromodomain containing 
protein 2; CETP, Cholesteryl ester transfer protein; DUSP10, 
Dual specificity protein phosphatase 10; KCNQ1, Potassium 
voltage–gated channel subfamily q member 1;  LEP & LEPR, 
Leptin and leptin receptor gene; MTHFR, 
Methylenetetrahydrofolate reductase; TOX2, TOX high 
mobility group box family member 2; TBX21, T-box 




racial label Black may not capture inter-continental 
admixture (Baker et al., 2017). We also acknowledge 
that ancestral diversity may influence a population’s 
cardiometabolic disease (CMD) risk suggesting that 
some of the susceptibility to CMD-related traits or 
diseases may be influenced by genetic factors, which 
may be ancestry-specific (Fernández-Rhodes et al., 
2020). Thus, given differences in allele frequencies 
across populations, estimating and accounting for 
ancestral diversity is necessary for appropriately 
determining the influence of genetic factors on CMD 
(Fernández-Rhodes et al., 2020). However, as this is 
beyond the scope of this review, further investigations 
assessing the impact of ancestral diversity on CMD risk 
in specific populations are necessary. 
 
FURTHER RESEARCH 
Based on the limitations identified in this review, we 
recommend the following for further research: 
• Prevalence of MHO in Africans living in Africa. 
• Genetic studies to evaluate the role of TBOX in 
MHO individuals of different ethnic groups. 
• The differential expression of DUSP10 in people of 
Asian, African, Arabian and Caucasian descent. 
• KCNQ1 rs2237892 C-T polymorphism among 
Africans and indigenes of the Middle East. Previous 
genetic studies included African 
Americans/Caribbean as the sole representative of 
Africans. Much of the available data are those 
obtained from Caucasians and Asians. 
• GWAS of ADIPOQ rs1501299 T allele in different 
racio-ethnic groups. 
• Deficiency of BRD2 gene in MHO humans. 
 
CONCLUSION 
As highlighted in this review, the available 
data/evidence show that MHO prevalence differs 
amongst racio-ethnic groups. This also supports existing 
data on prevalence of MetS in different racio-ethnic 
groups. Lower prevalence of MHO across all ages was 
particularly reported in the Middle East, while high 
prevalence was reported in African, American and some 
Asian adult population. Excluding environmental and 
other risk factors, we observed that genetic 
predisposition influences the MHO phenotype across 
different racio-ethnic groups. Africans had the lowest 
frequency of MTHFR C677T T allele that increases 
MetS risk compared to their European and Asian 
counterparts. Despite high MHO prevalence in Africans 
in the reported/included studies, they had the lowest 
frequency of the cardioprotective gene variant CETP 
Taq1B B2 allele. On the other hand, Europeans who had 
highest frequency of MTHFR C677T T allele, also 
showed favourable frequencies of cardioprotective gene 
variants and SNPs including increased LEPR Q223R A 
and CETP Taq1B B2 alleles; and low APOA5 rs662799 
C and G alleles. Furthermore, the low MHO prevalence 
across all age groups in the Middle East was supported 
by highest frequency of MTHFR C677T T. However, 
they also had the highest frequency of the 
cardioprotective LEPR Q223R A allele. Overall, Asians 
had higher frequencies of gene variants and SNPs 
(APOA5 rs662799 C and G allele, LEPR Q223R Aʹ 
allele, MTHFR C677T T allele and KCNQ1 rs2237892) 
that increase the risk of MetS, thereby decreasing 
metabolic health.  
Gene variants and SNPs for TOX2, DUSP10 and BRD2 
that improve MHO phenotype across different 
ethnicities are still unknown.  Investigating potential 
gene variants/SNPs for these genes among both 
metabolically healthy and unhealthy populations in 
different racio-ethnic groups is necessary. A more robust 
understanding of the role of these gene variants/SNPs, 
their frequency distribution and racio-ethnic variations 
may facilitate conceptualisation of appropriate GWAS 
to determine significant associations between various 
genetic factors and observed phenotype or disease. This 
will guide policy formulation and serve as a useful tool 
in pharmacogenomics and precision medicine. 
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